Latigo Biotherapeutics Inc. (LTGO)
Latigo Biotherapeutics Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Thousand Oak, CA, US. The stock last traded at $13.00, down 1.81% on the session, giving a market capitalisation of $782.0M. On trailing twelve-month figures it carries a trailing P/E of -5.52, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Latigo Biotherapeutics Inc. is most often compared with the following Healthcare names: